

Correction

Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. *Pharmaceutics* 2022, 14, 2668

Amira Mansour¹, Mohamed Y. Mahmoud², Alaa F. Bakr³, Monira G. Ghoniem⁴ , Fatima A. Adam⁴ and Ibrahim M. El-Sherbiny^{1,*} 

¹ Nanomedicine Research Labs, Center for Materials Science, Zewail City of Science & Technology, Giza 12578, Egypt

² Department of Toxicology and Forensic Medicine, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt

³ Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt

⁴ Department of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia

* Correspondence: ielsherbiny@zewailcity.edu.eg

In the original publication [1], specifically in Section 2.9. In Vivo Assessment, paragraph 1, lines 2–4, there is a need to correct some details in the ethical approval of the in vivo study.

We also highlighted the changes in Section 2.9. In Vivo Assessment, paragraph 1, lines 2–4, as well as in the Institutional Review Board Statement, with the following text.

“The in vivo experiment was performed after receiving the approval from the Institutional Animal Care and Use Committee (ARC-IACUC), Cairo, Egypt (protocol number: ARC-AH-22-29)”

“**Institutional Review Board Statement:** The in vivo experiment was performed after receiving the approval from the Institutional Animal Care and Use committee (ARC-IACUC), Cairo, Egypt (Protocol number: ARC-AH-22-29) that complies with the United Kingdom Animals Scientific Procedures Act, 1986, and the European Union directive 2010/63/EU for animal experiments, as well as the ARRIVE guidelines.”

The authors apologize for any inconvenience caused and the state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

1. Mansour, A.; Mahmoud, M.Y.; Bakr, A.F.; Ghoniem, M.G.; Adam, F.A.; El-Sherbiny, I.M. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. *Pharmaceutics* **2022**, *14*, 2668. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.



Citation: Mansour, A.; Mahmoud, M.Y.; Bakr, A.F.; Ghoniem, M.G.; Adam, F.A.; El-Sherbiny, I.M. Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. *Pharmaceutics* **2022**, *14*, 2668. *Pharmaceutics* **2023**, *15*, 994. <https://doi.org/10.3390/pharmaceutics15030994>

Received: 8 March 2023

Accepted: 13 March 2023

Published: 20 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).